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Somatic rearrangements contribute to the mutagenized landscape of human cancer 
genomes. Here, we systematically interrogated catalogues of somatic rearrangements 
of 560 breast cancers1 to identify hotspots of recurrent rearrangements, specifically 
tandem duplications, because of previous anecdotal reports of tandem duplications 
that recurred in different patients. We highlight 33 rearrangement hotspots associated 
with a signature of Homologous Recombinational (HR) repair deficiency, 
characterized mainly by large (>100kb) tandem duplications. These hotspots are 
enriched for breast cancer germline susceptibility loci and breast-specific “super-
enhancer” regulatory elements, and have a propensity for wholly duplicating these 
genomic features as well as well-known breast cancer oncogenes. They could 
represent sites of selective susceptibility to rearrangement mutagenesis and through 
incrementally increasing copy number, represent sites of secondary selective pressure. 
Corroborative transcriptomic evidence was observed ranging from strong individual 
oncogene effects through to weak but quantifiable global gene expression effects. 
Furthermore, in an independent cohort of WGS ovarian cancers, seven long tandem 
duplication hotspots were detected that intriguingly demonstrated enrichment for 
ovarian-specific super enhancers. We thus present these tandem duplication hotspots 
as evidence of a rearrangement signature that exerts its influence through the coding 
sequence and through non-coding regulatory elements, contributing a continuum of 
consequences ranging from inconsequential through to strong oncogenic effects, 
making this rearrangement mutational process particularly deleterious.  
 
 
 
 
 
 
 
 
Introduction 
 
Whole genome sequencing (WGS) has permitted unrestricted access to the human 
cancer genome, triggering the hunt for driver mutations that could confer selective 
advantage in all parts of human DNA. Recurrent somatic mutations in coding 
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sequences are often interpreted as driver mutations particularly when supported by 
transcriptomic changes or functional evidence. However, recurrent somatic mutations 
in non-coding sequences are less straightforward to interpret. Although TERT 
promoter mutations in malignant melanoma2,3 and NOTCH1 3’ region mutations in 
chronic lymphocytic leukaemia4 have been successfully demonstrated as driver 
mutations, multiple non-coding loci have been highlighted as recurrently mutated but 
evidence supporting these as true drivers remains lacking. Indeed, in a recent 
exploration of 560 breast cancer whole genomes1, the largest cohort of WGS cancers 
to date, statistically significant recurrently mutated non-coding sites (by substitutions 
and insertions/deletions (indels)) were identified but alternative explanations for 
localized elevation in mutability such as a propensity to form secondary DNA 
structures were observed1.  
 
These efforts have been focused on recurrent substitutions and indels and an exercise 
seeking sites that are recurrently mutated through rearrangements has not been 
formally performed. Such sites could be indicative of driver loci under selective 
pressure (such as amplifications of ERBB2 and CCND1) or could represent highly 
mutable sites that are simply prone to double-strand break (DSB) damage. Sites that 
are under selective pressure generally have a high incidence in a particular tissue-
type, are highly complex and comprise multiple classes of rearrangement including 
deletions, inversions, tandem duplications and translocations. By contrast, sites that 
are simply breakable may show a low frequency of occurrence and demonstrate a 
preponderance of a particular class of rearrangement, a harbinger of susceptibility to a 
specific mutational process.  
 
An anecdotal observation in the cohort of 560 breast cancers was of sites in the 
genome that appeared to be rearranged recurrently, albeit at a low frequency, and by a 
very specific rearrangement class of tandem duplications. Rarely, tandem duplications 
recurred at approximately the same locus in the same cancer resulting in the 
appearance of nested tandem duplications. No explanation was provided for this 
observation. Here, we have taken a novel approach to systematically seek sites in the 
human cancer genome that are recurrently mutagenized by rearrangements, 
specifically tandem duplications, in order to fully understand the prevalence and the 
impact of these sites of recurrent tandem duplications in this cohort of breast cancers.  
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In all, 77,695 rearrangements including 59,900 intra-chromosomal (17,564 deletions, 
18,463 inversions and 23,873 tandem duplications) and 17,795 inter-chromosomal 
translocations were identified in this cohort previously. The distribution of 
rearrangements within each cancer was complex (Figure 1A-D); some had few 
rearrangements without distinctive patterns, some had collections of focally occurring 
rearrangements such as amplifications, whereas many had rearrangements distributed 
throughout the genome - indicative of very different set of underpinning mutational 
processes. 
 
Thus, large, focal collections of “clustered” rearrangements were first separated from 
rearrangements that were widely distributed or “dispersed” in each cancer, then 
distinguished by class (inversion, deletion, tandem duplication or translocation) and 
size (1-10kb, 10-100kb, 100kb-1Mb, 1-10Mb, more than 10Mb)1, before a 
mathematical method for extracting mutational signatures was applied5. Six 
rearrangement signatures were extracted (RS1-RS6) representing discrete 
rearrangement mutational processes in breast cancer1. Two distinctive mutational 
processes in particular were associated with dispersed tandem duplications. RS1 and 
RS3 are mostly characterized by large (>100kb) and small  (< 10kb) tandem 
duplications, respectively (Figure 1E). Although both are associated with tumors that 
are deficient in homologous recombination (HR) repair6-9, RS3 is specifically 
associated with inactivation of BRCA1. Thus, because they represent distinct 
biological defects in human cells, we have chosen to proceed with a systematic 
analysis of sites of recurrent mutagenesis of these two mutational signatures as 
independent processes.  
 
We identified a surprising number of rearrangement hotspots dominated by the RS1 
mutational process characterised by long (>100kb) tandem duplications1.  Intuitively, 
a hotspot of mutagenesis that is enriched for a particular mutational signature implies 
a propensity to DNA double-strand break (DSB) damage and specific recombination-
based repair mutational mechanisms that could explain these tandem duplication 
hotspots. However, we find additional intriguing features associated with these 
hotspots that challenge current perceptions in cancer biology, explained below.  
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Results 
 
Identification of rearrangement hotspots 
 
In order to systematically identify hotspots of tandem duplications through the 
genome, we first considered the background distribution of rearrangements that is 
known to be non-uniform. A regression analysis was performed to detect and quantify 
the associations between the distribution of rearrangements and a variety of genomic 
landmarks including replication time domains, gene-rich regions, background copy 
number, chromatin state and repetitive sequences (Supplementary materials and 
Supplementary Figure S1). The associations learned were taken into consideration 
creating an adjusted background model and were also applied during simulations, 
these steps being critical to the following phase of hotspot detection. Adjusted 
background models and simulated distributions were calculated for RS1 and RS3 
tandem duplication signatures separately because of vastly differing numbers of 
rearrangements in each signature of 5,944 and 13,498 respectively, which could bias 
the detection of hotspots for the different signatures.  
 
We next employed the principle of intermutation distance10 (IMD)- the distance from 
one breakpoint to the one immediately preceding it in the reference genome and used 
a piece-wise constant fitting (PCF) approach11,12, a method of segmentation of 
sequential data that is frequently utilised in analyses of copy number data.  PCF was 
applied to the IMD of RS1 and RS3 separately, seeking segments of the breast cancer 
genomes where groups of rearrangements exhibited short IMD, indicative of 
“hotspots” that are more frequently rearranged than the adjusted background model 
(Figure 2, Supplementary Materials). The parameters used for the PCF algorithm 
were optimised against simulated data (Supplementary Materials and Supplementary 
Figure S2). We aimed to detect a conservative number of hotspots while minimising 
the number of false positive hotspots. Note that all highly clustered rearrangements 
such as those causing driver amplicons had been previously identified in each sample 
and removed, and thus do not contribute to these hotspots. However, to ensure that a 
hotspot did not comprise only a few samples with multiple breakpoints each, a 
minimum of eight samples was required to contribute to each hotspot. Of note, this 
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method negates the use of genomic bins and permits detection of hotspots of varying 
genomic size. 
 
Thus, the PCF method was applied to RS1 and RS3 rearrangements separately, 
seeking loci that have a rearrangement density exceeding twice the local adjusted 
background density for each signature and involving a minimum of eight samples. 
Interestingly, 0.5% of 13,498 short RS3 tandem duplications contributed towards four 
RS3 hotspots. By contrast, 10% of 5,944 long RS1 tandem duplications formed 33 
hotspots demonstrating that long RS1 tandem duplications are 20 times more likely to 
form a rearrangement hotspot than short RS3 tandem duplications. Indeed, these were 
visible as punctuated collections of rearrangements in genome-wide plots of 
rearrangement breakpoints (Figure 2C and Supplementary Table S1).   
 
 
Contrasting RS3 hotspots to RS1 hotspots 
 
RS3 hotspots had different characteristics to that of RS1 hotspots. The four RS3 
hotspots were highly focused, occurred in small genomic windows and exhibited very 
high rearrangement densities (range 61.8 to 658.3 breakpoints per Mb (Figure 3B). In 
contrast, the 33 RS1 hotspots had densities between 7.6 and 83.2 breakpoints per Mb 
and demonstrated other striking characteristics (Figure 3A). In several RS1 hotspots, 
duplicated segments showed genomic overlap between patients, even when most 
patients had only one tandem duplication, as depicted in a cumulative plot of 
duplicated segments for samples contributing rearrangements to a hotspot (Figure 3C, 
Supplementary Figure S3).  Interestingly, the nested tandem duplications that were 
observed incidentally in the past, were a particular characteristic of RS1 hotspots.  
The hotspots of RS1 and RS3 were distinct from one another apart from one locus 
where two lncRNAs NEAT1 and MALAT1 reside (discussed in Section 7 of 
Supplementary Materials).   
 
Assessing the potential genomic consequences of RS1 and RS3 tandem duplications 
on functional components of the genome, RS1 rearrangements were observed to 
duplicate important driver genes and regulatory elements while RS3 rearrangements 
were found to mainly transect them (Supplementary materials section 8 and Figure 4). 
This is likely to be related to the size of tandem duplications in these signatures. Short 
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(<10kb) RS3 tandem duplications are more likely to duplicate very small regions, 
with the effect equivalent of disrupting genes or regulatory elements. In contrast, RS1 
tandem duplications are long (>100kb), and would be more likely to duplicate whole 
genes or regulatory elements.  
 
Strikingly, the effects were strongest for tandem duplications that contributed to 
hotspots of RS1 and RS3 than they were for tandem duplications that were not in 
hotspots or that were simulated. Thus, although the likelihood of 
transection/duplication may be governed by the size of tandem duplications, the 
particular enrichment for hotspots must carry important biological implications.  
 
The enrichment of disruption of tumour suppressor genes by RS3 hotspots (OR 167, 
P=9.4 × 10-41 by Fisher’s exact test) and is relatively simple to understand - these are 
likely to be under selective pressure. Accordingly, two of the four RS3 hotspots 
occurred within well-known tumour suppressors, PTEN and RB1. Other 
rearrangement classes are also enriched in these genes in-keeping with being driver 
events (Section 7 of Supplementary Materials, Supplementary Table S2). 
Furthermore, these sites were identified as putative driver loci in an independent 
analysis seeking driver rearrangements through gene-based methods1.  
 
By contrast, the enrichment of oncogene duplication by RS1 hotspots (OR 1.49, 
P=4.1 × 10-3  by Fisher’s exact test) was apparent13, although not as strong as the 
enrichment of transections of cancer genes by RS3 hotspots. More notably, the 
enrichment of other putative regulatory features was also observed. Indeed, we 
observed that susceptibility loci associated with breast cancer14,15 were 4.28 times 
more frequent in an RS1 hotspot than in the rest of the tandem duplicated genome 
(Supplementary Figure S4A, P=3.4 × 10-4 in Poisson test). Additionally, 18 of 33 
(54.5%) RS1 tandem duplication hotspots contained at least one breast super-
enhancer. The density of breast super-enhancers was 3.54 times higher in a hotspot 
compared to the rest of the tandem duplicated genome (Supplementary Figure S4B,  
P=7.0 × 10-16 Poisson test). This effect was much stronger than for non-breast tissue 
super-enhancers (OR 1.62) or enhancers in general (OR 1.02, Supplementary Table 
S3). This gradient reinforces how the relationship between tandem duplication 
hotspots and regulatory elements deemed as super-enhancer, is tissue-specific. 
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The reason underlying these observations in RS1 hotspots however is a little less 
clear. Single or nested tandem duplications in RS1 hotspots effectively increase the 
number of copies of a genomic region but only incrementally. The enrichment of 
breast cancer specific susceptibility loci, super-enhancers and oncogenes at hotspots 
of a very particular mutational signature could reflect an increased likelihood of 
damage and thus susceptibility to a passenger mutational signature that occurs 
because of the high transcriptional activity associated with such regions. However, it 
is also intriguing to consider that the resulting copy number increase could confer 
some more modest selective advantage and contribute to the driver landscape.  To 
investigate the latter possibility, we explored the impact of RS1 tandem duplications 
on gene expression. 
 
 
 
Impact of RS1 hotspots on expression 
 
Several RS1 hotspots involved validated breast cancer genes (e.g. ESR1, ZNF217, 
Supplementary Figure S6, S7) and could conceivably contribute to the driver 
landscape through increasing the number of copies of a gene - even if by only a single 
copy.  
 
ESR1 is an example of a breast cancer gene that is a target of an RS1 hotspot. In the 
vicinity of ESR1 is a breast tissue specific super-enhancer and a breast cancer 
susceptibility locus. Fourteen samples contribute to this hotspot, of which ten have 
only a single tandem duplication or simple nested tandem duplications of this site. Six 
samples had expression data and all showed significantly elevated levels of ESR1 
despite modest copy number increase (Supplementary Figure S6a). Four samples have 
a small number of rearrangements (< 30) yet have a highly specific tandem 
duplication of ESR1, suggestive of selection. Most other samples with rearrangements 
in the other 32 hotspots were triple negative tumours. By contrast, samples with 
rearrangements in the ESR1 hotspot showed a different preponderance – eleven of 
fourteen were estrogen receptor positive tumours.  Thus we propose that the 
duplications in the ESR1 hotspot are putative drivers that would not have been 
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detected using customary copy number approaches previously, but are likely to be 
important to identify because of the associated risk of developing resistance to anti-
estrogen chemotherapeutics16,17. 
 
c-MYC encodes a transcription factor that coordinates a diverse set of cellular 
programs and is deregulated in many different cancer types18,19. 30 patients 
contributed to the RS1 hotspot at the c-MYC locus with modest copy number gains. A 
spectrum of genomic outcomes was observed including single or nested tandem 
duplications, flanking (16 samples) or wholly duplicating the gene body of c-MYC (14 
samples) (Figure 5A). Notably, a breast tissue super-enhancer and two germline 
susceptibility loci lie in the vicinity of c-MYC 20 15(Figure 5B). We had a larger 
number of samples with corresponding RNA-seq data and thus modeled the 
expression levels of c-MYC taking breast cancer subtype, background copy number 
(whole chromosome arm gain is common for chr 8) and sought whether tandem 
duplicating a gene was associated with increased transcription. We find that tandem 
duplications in the RS1 hotspot were associated with a doubling of   the expression 
level of c-MYC (0.99 s.e. 0.28 log2 FPKM, P=4.4 × 10-4  in t-test)  (Supplementary 
Table S4).  
 
The expression–related consequences of tandem duplications of putative regulatory 
elements however, is more difficult to assess because of the uncertainty of the 
downstream targets of these regulatory elements. We have thus taken a global gene 
expression approach and applied a mixed effects model to understand the contribution 
of tandem duplications of these elements, controlling for breast cancer subtype and 
background copy number. We find that tandem duplications involving a super-
enhancer or breast cancer susceptibility locus are associated with an increase in levels 
of global gene expression even when the gene itself is not duplicated. The effect is 
strongest on oncogenes (0.30 +- 0.20 log2 FPKM, P=0.12 in ANOVA test) than for 
other genes (0.16 s.e. 0.04 log2 FPKM, P=1.8 × 10-4  in ANOVA test) within RS1 
hotspots or for genes in the rest of the genome (Supplementary Table S4).  
 
Thus, tandem duplications of cancer genes demonstrate strong expression effects in 
individual genes (e.g. ESR1 and c-MYC) while tandem duplications of putative 
regulatory elements demonstrate modest but quantifiable global gene expression 
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effects. The spectrum of functional consequences at these loci could thus range from 
insignificance, through mild enhancement, to strong selective advantage – 
consequences of the same somatic rearrangement mutational process.  
 
 
Long tandem duplication hotspots are present and distinct in other cancers 
 
We additionally explored other cancer cohorts where sequence files were available. 
Two cancer types are known to exhibit tandem duplications, particularly pancreatic 
and ovarian cancers. Raw sequence files were parsed through our mutation-calling 
algorithms and rearrangement signatures extracted as for breast cancers. Adjusted 
background models and simulations were performed on these new datasets separately. 
The total number of available samples was much smaller than the breast cancer 
cohort, which is currently the largest cohort of WGS cancers of a single cancer type in 
the world. Thus power for detecting hotspots was substantially reduced particularly 
for pancreatic cancer. Nevertheless, in ovarian tumours 2,923 RS1 rearrangements 
were found and seven RS1 hotspots identified, of which six were distinct from breast 
cancer RS1 hotspots. A marked enrichment for ovarian cancer specific super-
enhancers (11 super-enhancers over 20.2 Mb, OR 2.9, P=1.9 × 10-3  in Poisson test) 
was also noted for these hotspots. MUC1, a validated oncogene in ovarian cancer was 
the focus at one of the hotspots. Thus, although we require larger cohorts of WGS 
cancers in the future to be definitive, the presentiment is that different cancer-types 
could have different RS1 hotspots that are focused at highly transcribed sites specific 
to different tissues. 
 
Discussion: Selective susceptibility or selective pressure? 
 
Rearrangement signatures may, in principle, be mere passenger read-outs of the 
stochastic mayhem in cancer cells. However, mutational signatures recurring at 
specific genomic sites, which also coincide with distinct genomic features, suggest a 
more directed nature – a sign of either selective susceptibility or selective pressure. 
 
Perhaps it is an attribute of being more highly active or transcribed (e.g. super-
enhancers) or some other as yet unknown quality (e.g. germline SNP sites and other 
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hotspots with no discerning features), these hotspots exemplify loci that are rendered 
more available for DSB damage and more dependent on repair that generates large 
tandem duplications6,21-23. They signify genomic sites that are innately more 
susceptible to the HR-deficient tandem duplication mutational process – sites of 
selective susceptibility.  
 
An alternative argument could also hold true: It could be that the likelihood of 
damage/repair relating to this mutational process is similar throughout the genome. 
However, through incrementally increasing the number of copies of coding genes that 
drive tissue proliferation, survival and invasion (ESR1, ZNF217) or non-coding 
regions that have minor or intermediate modifying effects in cancer such as germline 
susceptibility loci or super-enhancer elements, long tandem duplications (unlike other 
classes of rearrangements) could specifically enhance the overall likelihood of 
carcinogenesis. The profound implication is that these loci do come under a degree of 
selective pressure, and that this HR-deficient tandem duplication mutational process is 
in fact a novel mechanism of generating secondary somatic drivers.  
 
Functional activity related to being a super-enhancer or SNP site could underlie 
primary susceptibility to mutagenesis of a given locus, but it requires a repair process 
that generates large tandem duplications to confer selective advantage (Figure 5C). 
Tandem duplication mutagenesis is associated with DSB repair in the context of HR 
deficiency and is a potentially important mutagenic mechanism driving genetic 
diversity in evolving cancers by increasing copy number of portions of coding and 
non-coding genome. It could directly increase the number of copies of an oncogene or 
alter non-coding sites where super-enhancers/risk loci24 are situated. It could therefore 
produce a spectrum of driver consequences25,26, ranging from strong effects in coding 
sequences to weaker effects in the coding and non-coding genome, profoundly, 
supporting a polygenic model of cancer development.  
 
 
Conclusions 
 
Structural mutability in the genome is not uniform. It is influenced by forces of 
selection and by mutational mechanisms, with recombination-based repair playing a 
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critical role in specific genomic regions.  Mutational processes may however not 
simply be passive contrivances. Some are possibly more harmful than others. We 
suggest that mutation signatures that confer a high degree of genome-wide variability 
are potentially more deleterious for somatic cells and thus more clinically relevant. 
Translational efforts should be focused on identifying and managing these adverse 
mutational processes in human cancer.  
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Figure legends 
 
Figure 1: Spectrum of distribution of rearrangements in human breast cancers. 
Circos plots depicting somatic rearrangements with chromosomal ideogram on 
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the outermost right and lines representing rearrangements (green= tandem 
duplications, pink=deletions, blue=inversions and purple=interchromosomal events). 
A, quiescent tumor, B, tumor with focal “clustered” rearrangements, C, tumor with 
mainly tandem duplications distributed throughout the genome (“dispersed” 
rearrangements) D, tumor with a mixed pattern of dispersed rearrangements and 
clustered rearrangements. E, Rearrangement Signatures 1 and 3 comprise mainly 
tandem duplications but are characterised predominantly by tandem duplications of 
different lengths (>100kb and <10kb respectively). 
 
Figure 2: Identifying hotspots of rearrangements. A, A schematic of dispersed 
rearrangements in the genomes of 5 hypothetical patients, with regions that are 
identified as hotspots by the PCF algorithm highlighted in beige. Note the differing 
sizes of each putative hotspot permitted through this method that negates the use of 
bins. B, Workflow of PCF application to rearrangement signatures. C, Rainfall plots 
of chromosome 8 rearrangements for tandem duplication signatures RS1 (>100kb) top 
panel and RS3 (<10kb) bottom panel. Inter-rearrangement distance is plotted on a log-
scale on the y-axis. Black lines demonstrate PCF-defined hotspots. RS1 is 20 times 
more likely to form hotspots than RS3 and these are visible as punctuated collections 
of breakpoints in these plots.    
 
Figure 3: Hotspots of dispersed rearrangements: A large (>100kb) tandem 
duplication mutational process shows distinctive genomic overlap between 
patients and coincides with germline susceptibility loci and super-enhancer 
regulatory elements 
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A, A summary of 33 hotspots of long tandem duplications (RS1) and, B, 4 hotspots of 
short tandem duplications (RS3). Higher panel shows density of rearrangement 
breakpoints within hotspots. The black horizontal lines denote the expected 
breakpoint density according to the background model. Lower panel shows frequency 
of each hotspot in the cohort of 560 patients. Hotspots that contain breast cancer 
susceptibility SNPs are marked with blue circles, and breast-specific super-enhancers 
marked with red triangles. Genes that may be relevant are highlighted although their 
true significance is uncertain. C, Two different hotspots of RS1: left panel 
(chr12:11.8Mb-12.8Mb) coincides with two breast tissue specific super-enhancers 
and right panel (chr8:116.6Mb-117.7Mb) coincides with a germline susceptibility 
locus of breast cancer. Nearby cancer genes are annotated, although relevance of 
these genes is uncertain. Next six panels depict genomic rearrangements for six 
individual patients at each locus. Copy number (y-axis) depicted as black dots (10kb 
bins). Green lines present tandem duplication breakpoints. Note the precise genomic 
overlap between patients.  Lowermost panel presents cumulative number of samples 
with a rearrangement involving this genomic region, emphasizing at its peak, the 
region of critical genomic overlap between samples. Thick red lines represent breast-
tissue specific super enhancers. Blue vertical line represents position of germline 
susceptibility locus of breast cancer. Relevant SNP rsID is provided.  
 
Figure 4: Genomic consequences of the tandem duplication signatures 
Tandem duplications can transect or duplicate genomic features like regulatory 
elements or genes. A, tandem duplications attributed to rearrangement signature RS1 
often duplicate genomic regions containing breast cancer predisposition SNPs, breast 
tissue super-enhancers and oncogenes. RS1 rearrangements in hotspots show a 
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particular enrichment when compared to RS1 rearrangements that occur in other 
regions and when compared to simulated rearrangements.  There are 524 RS1 
duplications in hotspots, and 4,916 duplications outside of hotspots. B, tandem 
duplications attributed to RS3 in hotspots are enriched for transecting cancer genes 
more than in the rest of genome, or in simulated data. There are 57 RS3 duplications 
in hotspots, and 10,967 RS3 duplications outside of hotspots. Asterisks highlight 
statistically significant enrichment of any particular genomic feature within hotspots 
compared to outside hotspots, as calculated by two-sided Fisher’s exact test. Four 
asterisks **** denote p-value P<= 0.0001, ** P<=0.01, * P<=0.05 . Error bars show 
the standard deviation across ten different simulated datasets. 
 
Figure 5: From selective susceptibility to selective pressure? 
A, The spectrum of genomic structural variation at a single locus: c-MYC. Copy 
number (y-axis) depicted as black dots (10kb bins). Lines represent rearrangement 
breakpoints (green= tandem duplications, pink=deletions, blue=inversions and 
purple=interchromosomal events). Genes other than c-MYC were marked as black 
lines at the top of the panel. B, Cumulative number of samples with dispersed 
rearrangements within the c-MYC-related tandem duplication hotspot. A peak is 
observed very close to c-MYC but also flanking c-MYC where two germline 
susceptibility loci are observed. A large super-enhancer is also situated upstream of c-
MYC. C, Putative model of cascade of events underlying the RS1-enriched hotspots in 
breast cancer. Sites enriched for super-enhancers (SENH) may be more highly 
transcribed and thus exposed to damage including DSB damage. Long tandem 
duplications are particularly at risk of copying whole genes in contrast to other 
rearrangement classes. Thus although other rearrangement classes may be found (in 
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low numbers in the same region), an enrichment of long tandem duplications is 
observed because of a small degree of selection in action.  
 
